Somatropin - Altus Pharmaceuticals

Drug Profile

Somatropin - Altus Pharmaceuticals

Alternative Names: ALTU-238; Extended-release somatropin - Altus; hGH - Altus

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Altus Pharmaceuticals
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Somatotropin deficiency

Most Recent Events

  • 16 Jul 2013 Biomarkers information updated
  • 12 Nov 2012 Althea Technologies acquires the assets and IP portfolio of Altus Pharmaceuticals
  • 10 Jun 2009 Adverse events and pharmacokinetics data from a phase Ic trial in healthy adult volunteers presented at the 91st Annual Meeting of the Endocrine Society (ENDO-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top